Study Protocol: Impact of Metamizole (Optalgin®) on Anti-Xa Concentrations in Oncology Patients Receiving DOACs

Recruiting now · Not applicable

Conditions studied: Oncologic Diseases, Coagulation Defect, Pain Management

In brief

Evaluation of the Effect of metamizole (Optalgin®) on Anti-Xa Levels in Oncology Patients Receiving Direct Oral Anticoagulants (DOACs)

Key facts

Study ID

NCT07384013

Run by

Rambam Health Care Campus

People needed

30

Starts

2025-11-01

Expected to finish

2027-12-31

Last updated by the study team

2026-02-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult oncology patients (≥18 years old).
• Receiving apixaban or rivaroxaban for anticoagulation.
• New/current metamizole users taking at least 1g TID for pain management.
• Platelets ≥100×10⁹/L
• ECOG PS<3
• Provided informed consent

You may not qualify if…

• History of allergic reaction to metamizole or DOACs.
• Individuals with significant gastrointestinal disorders that may affect absorption, including (but not limited to) diagnosed bowel obstruction, persistent diarrhea, or the presence of a nasogastric tube (NGT/zonda)

Where it is running

• Rambam Health Care Campus — Haifa, Israel (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.